Skip to main content Skip to footer
Log in
Alma universitas studiorum parmensis A.D. 962 - Università di ParmaAlma universitas studiorum parmensis A.D. 962 - Università di Parma People and Organization
Università degli Studi di Parma

Andrea Blesio

Print
PhD student in SCIENZE MEDICHE E CHIRURGICHE TRASLAZIONALI, 41th cycle
Department of Medicine and Surgery

Presentazione

I am a PhD candidate in Translational Medical and Surgical Sciences at the Department of Medicine and Surgery, University of Parma, where I conduct research in the Laboratory of Experimental Oncology. My research focuses on human non-small cell lung cancer (NSCLC) cell lines harboring KRAS mutations, with particular interest in oncogenic signaling pathways, the development of drug resistance models, and the evaluation of novel targeted therapy strategies.

Curriculum Vitae

Download the CV

Andrea Blesio is a PhD candidate in Translational Medical and Surgical Sciences at the Department of Medicine and Surgery, University of Parma, where he conducts research in the Laboratory of Experimental Oncology.

He obtained his Master's Degree in Pharmaceutical Chemistry and Technology (CTF) with honors from the University of Parma. His master's thesis focused on the biological characterization and therapeutic perspectives of KRAS-mutant non-small cell lung cancer (NSCLC) cell lines.

His current research focuses on oncogenic signaling and therapeutic vulnerabilities in KRAS-mutant NSCLC, with particular emphasis on the development of drug resistance models and the evaluation of novel targeted therapy strategies. His experimental activities include 2D and 3D cell culture models, functional assays, flow cytometry, and molecular biology techniques.

He is the author of peer-reviewed scientific publications in the fields of experimental oncology and pharmacology. In 2026, he was awarded the Berlucchi International Mobility Award, supporting a research stay at the Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam.

Research

Research areas

Research activities focus on the molecular mechanisms driving KRAS-mutant non-small cell lung cancer (NSCLC), with particular emphasis on the KRAS G12D and KRAS G12V variants. Main research interests include the characterization of oncogenic signaling pathways, the identification of therapeutic vulnerabilities, and the evaluation of novel targeted therapy strategies.

Current work is also dedicated to the development and characterization of acquired resistance models to pan-RAS inhibitors, particularly RMC-6236, with the aim of elucidating the molecular mechanisms underlying drug resistance and identifying novel therapeutic targets for KRAS-driven cancers.

Publications